Less Than One in 20 Eligible Adults Receives Lung Cancer Screening

Lung cancer screening at the state level does not correlate with lung cancer burden

ALA: Lung Cancer Survival Has Increased Nationally to 22.6 Percent

People of color face worse outcomes, have lower likelihood of being diagnosed early, receiving surgery

Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC

Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib

Use of Common Meds Tied to Lower Lung Cancer Mortality Combined use of aspirin, statins, metformin tied to lower lung cancer risk and mortality

Atezolizumab Prolongs Survival in NSCLC With PD-L1 Expression Overall survival longer than for chemotherapy in metastatic NSCLC with high PD-L1 expression

Lung Cancer Treatment Plans Changed Due to Pandemic – 57 percent of patients receiving active treatment had at least one change in treatment plans

Certain HTN Meds May Cut Deaths From Influenza, Pneumonia

Use of ACE-I/ARB versus nonuse linked to lower mortality for those hospitalized with flu, pneumonia

One Size May Not Fit All for Postoperative Opioid Prescribing

Guidelines reduce postoperative opioid prescribing but may result in inadequate pain control for some

COVID-19-Free Surgical Pathways May Aid Cancer Surgery Outcomes

Pulmonary complication, postoperative SARS-CoV-2 infection rates lower with COVID-19-free pathways

More Than Half of Cancer Patients Willing to Enroll in Clinical Trials

Participation rates similar for Black and White patients, treatment and cancer control trials